Zobrazeno 1 - 10
of 43
pro vyhledávání: '"M, Björeman"'
Autor:
Bo Nilsson, Håkan Mellstedt, Bengt Smedmyr, H. Gyllenhammar, Bertil Johansson, Richard A. Lerner, Anders Österborg, C. Paul, Gunnar Juliusson, H. Strander, C. Wedelin, Eva Kimby, B. Wadman, G. Brenning, A.-M. Stalfelt, Anders Ahre, G. Gahrton, Andreas Killander, Erik Svedmyr, Magnus Björkholm, Bengt Simonsson, M. Björeman, M. Järnmark, A.-M. Udén
Publikováno v:
European Journal of Haematology. 43:54-62
86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44). The treatment gropus were wel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d569cf195418dd6be015ed13188ab7cd
https://doi.org/10.1111/j.1600-0609.1989.tb01252.x
https://doi.org/10.1111/j.1600-0609.1989.tb01252.x
Autor:
Håkan Mellstedt, Gunnar Juliusson, Eva Ösby, Bengt Simonsson, Bengt Smedmyr, C. Paul, B. Wadman, Bertil Johansson, Erik Svedmyr, H. Strander, Magnus Björkholm, M. Björeman, H. Gyllenhammar, Andreas Killander, Karl Merk, G. Brenning, G. Grimfors, G. Gahrton, A.-M. Stalfelt, Eva Kimby, Richard A. Lerner, M. Järnmark, A.-M. Udén, Anders Österborg, R. Hast
Publikováno v:
European Journal of Haematology. 43:124-128
A randomized study comparing melphalan/prednisone (M/P) therapy with MP + natural alpha-IFN in untreated patients with multiple myeloma stages II and III started April 1, 1986. By March 1989, 78 patients were evaluable in the MP group and 80 in the M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d65561e3fc0b7d41c6c86c06ff099e
https://doi.org/10.1111/j.1600-0609.1989.tb01504.x
https://doi.org/10.1111/j.1600-0609.1989.tb01504.x
Autor:
Gunnar Öberg, G. Gahrton, Richard A. Lerner, Astrid Gruber, C. Paul, A.-M. Stalfelt, Ulf Tidefelt, Magnus Björkholm, G. Grimfors, Bengt Simonsson, S. Mattson, A.-M. Udén, Robert Hast, Leif Stenke, Jan Liliemark, M. Björeman, Andreas Killander
Publikováno v:
European Journal of Haematology. 68:376-381
It is still controversial how to treat elderly patients with acute myeloid leukaemia (AML), and results have been poor with most regimens. We report the long-term results of a randomised study performed by the Leukaemia Group of Middle Sweden during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71cb222d566d088b061f4161ab0bd95e
https://doi.org/10.1034/j.1600-0609.2002.00423.x
https://doi.org/10.1034/j.1600-0609.2002.00423.x
Autor:
G, Oberg, A, Killander, M, Björeman, G, Gahrton, G, Grimfors, A, Gruber, R, Hast, R, Lerner, J, Liliemark, S, Mattson, C, Paul, B, Simonsson, A-M, Stalfelt, L, Stenke, U, Tidefelt, A-M, Udén, M, Björkholm
Publikováno v:
European journal of haematology. 68(6)
It is still controversial how to treat elderly patients with acute myeloid leukaemia (AML), and results have been poor with most regimens. We report the long-term results of a randomised study performed by the Leukaemia Group of Middle Sweden during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfc292e903068aae72df282b2272bba1
https://pubmed.ncbi.nlm.nih.gov/12225396
https://pubmed.ncbi.nlm.nih.gov/12225396
Autor:
Håkan Mellstedt, Anders Österborg, Kristina Carlson, M. Ohrling, K. Engman, Eva Ösby, Eva Kimby, Jan Samuelsson, M. Björeman
Publikováno v:
European Journal of Haematology. 47:234-235
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95fa81bd55d93fe40d18ad79a8cf2b23
https://doi.org/10.1111/j.1600-0609.1991.tb01561.x
https://doi.org/10.1111/j.1600-0609.1991.tb01561.x
Autor:
B, Simonsson, G, Oberg, A, Killander, M, Björeman, M, Björkholm, G, Gahrton, L, Stenke, I, Turesson, A M, Udén, C, Malm
Publikováno v:
Bone marrow transplantation. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b4f5769556d03fffb1ca9f2eecfffbd7
https://pubmed.ncbi.nlm.nih.gov/7535154
https://pubmed.ncbi.nlm.nih.gov/7535154
Autor:
M. Järnmark, H. Gyllenhammar, A.-M. Udén, Bengt Smedmyr, G. Brenning, Kristina Carlson, Astrid Gruber, M. Ohrling, R. Hast, C. Paul, Anders Österborg, Fredrik Celsing, G. Gahrton, Bengt Simonsson, Eva Kimby, Olle Linder, Bertil Johansson, Gunnar Juliusson, Richard A. Lerner, M. Björeman, Karl Merk, Håkan Mellstedt, Eva Ösby, Erik Svedmyr, Magnus Björkholm, A.-M. Stalfelt, G. Grimfors
Publikováno v:
European journal of haematology. 51(1)
Fifty-six patients with refractory multiple myeloma were treated with intermittent courses of etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) every 4th week. The overall response rate was 30%. Durable remissions exceeding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235ded88f3aa071a7191dd011072e0e3
https://pubmed.ncbi.nlm.nih.gov/8348944
https://pubmed.ncbi.nlm.nih.gov/8348944
Autor:
Enrica Morra, David Marin, Mauricette Michallet, Gregor Verhoef, M. Björeman, Juan Luis Steegmann, K. Cerri, T. Kühr, M. Sterckx, Gert J. Ossenkoppele
Publikováno v:
Journal of Clinical Oncology. 26:7077-7077
7077 Background: Imatinib (IM) is widely used to treat CML. The Unmet Needs in CML study assessed real-life treatment of CML. Methods: This cross-sectional study, with retrospective chart review of...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb9ab9c89f5003f6daf11c75c957a64a
https://doi.org/10.1200/jco.2008.26.15_suppl.7077
https://doi.org/10.1200/jco.2008.26.15_suppl.7077
Autor:
Robert Hast, A.-M. Stalfelt, B. Johansson, Christer Paul, A. Killander, Gunnar Juliusson, M. Björeman, Håkan Mellstedt, G. Gahrton, G. Brenning, B. Simonsson, E. Svedmyr, B. Smedmyr, Eva Ösby, Magnus Björkholm, M. Järnmark, A.-M. Udén, A. Åhre, Bo Nilsson, B. Wadman, Anders Österborg, Eva Kimby, Gunnar Grimfors, R. Lerner, H. Gyllenhammar
Publikováno v:
Acta oncologica (Stockholm, Sweden). 29(6)
Eighty-one previously untreated patients with multiple myeloma stage II entered a randomized trial comparing oral melphalan (0.25 mg/kg/day; n = 40) with intravenous melphalan (0.125 mg/kg/day; n = 41) in combination with oral prednisone (2 mg/kg/day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8309d3b6d3d368815820841eab9d7d99
https://pubmed.ncbi.nlm.nih.gov/2223143
https://pubmed.ncbi.nlm.nih.gov/2223143
Publikováno v:
Plasma Therapy and Transfusion Technology. 9:89-94
Thrombotic thrombocytopenic purpura (TTP) is presently regarded as one of the most clearcut indications for plasma exchange (PE). We describe a young woman with TTP during pregnancy who initially received PE but during the last months of her pregnanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af95545fc89e3a1852a128867dfd722
https://doi.org/10.1016/0278-6222(88)90039-3
https://doi.org/10.1016/0278-6222(88)90039-3